Left Menu
Development News Edition

Sun Pharma gets DCGI approval for clinical trial with Nafamostat in Covid-19 patients

Sun Pharmaceutical Industries said on Friday it has received approval from the Drugs Controller General of India (DCGI) to initiate clinical trial with Nafamostat Mesilate in Covid-19 patients.

ANI | Mumbai (Maharashtra) | Updated: 29-05-2020 15:40 IST | Created: 29-05-2020 15:40 IST
Sun Pharma gets DCGI approval for clinical trial with Nafamostat in Covid-19 patients
The company has 42 manufacturing facilities across six continents. Image Credit: ANI

Sun Pharmaceutical Industries said on Friday it has received approval from the Drugs Controller General of India (DCGI) to initiate clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of disseminated intravascular coagulation (DIC).

A group of scientists from the University of Tokyo in Japan and Leibniz Institute for Primate Research inGermany recently demonstrated that Nafamostat at very low concentrations suppresses a protein (TMPRSS2) that the Covid-19 virus uses to enter human lung cells. Another group from Institut Pasteur in South Korea also published data comparing antiviral efficacy of 24 drugs and Nafamostat against SARSCoV-2 in in-vitro studies in human lung epithelial derived cells.

In this research, Nafamostat was found to be the most potent drug and was able to inhibit virus entry at very low concentrations, consistent with findings from Japan and German labs. Globally, there are three clinical trials currently underway to test Nafamostat in Covid-19 patients. Thesetrials are being led by the University of Tokyo Hospital in Japan, Gyeongsang National University Hospital in South Korea, and a collaborative trial by University Hospital at Padova in Italy, University of Zurich inSwitzerland and Yokohoma City University in Japan.

Considering the pandemic situation and urgent need for newer treatment options, Sun Pharma plans toinitiate the clinical trials at the earliest. The company has initiated manufacturing of both, the active pharma ingredient and the finished product of Nafamostat in India, using technology from its subsidiary, Pola Pharma Japan. "Sun Pharma is constantly evaluating potential targets that can be explored for treating Covid-19 patients," said Managing Director Dilip Shanghvi.

"Nafamostat has shown promising data against SARS-CoV-2 virus in in vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea. We believe it holds promise in the treatment of Covid-19 patients," he said in a statement. Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Delivering products for customers and patients in over 100 countries, its global presence is supported by manufacturing facilities spread across six continents which are approved by multiple regulatory agencies. (ANI)


TRENDING

OPINION / BLOG / INTERVIEW

COVID-19 seems cooking biggest ever global scam

The increasing number of corruption cases on COVID-19 funds from throughout the world and involvement of high profile persons indicate that the countries cant ignore corruption in their pandemic response programs. This has generated the nee...

Health Management Information Systems lack holistic, integrated, and pandemic resilient character

Being a part of the United Nations system, the World Health Organization WHO deserves its share of rebuke for its alleged failure issue COVID-19 health emergency alerts on appropriate time. However, the pandemic has also exposed loopholes i...

Pride in the time of coronavirus: a welcome move online?

This year is different in many ways not least as celebrations are also taking place against the dramatic backdrop of a global health crisis and a resurgence in grassroots activism following the death of George Floyd in Minneapolis. ...

COVID-19: Weighing up the benefits and limitations of edtech platforms

Edtech companies shouldnt focus on merely pushing contents, but to provide an interactive, effective teaching and learning environment. ...

Videos

Latest News

Israeli leader's son takes center stage in corruption sagas

As scandal-plagued Prime Minister Benjamin Netanyahu stands trial for corruption, his 28-year-old son has emerged as a driving force in a counterattack against critics and the state institutions prosecuting the longtime Israeli leader. A fa...

One of two Seattle protesters hit by car dies, other in ICU

Two female protesters in Seattle were hit on Saturday by a speeding car that drove into a crowd demonstrating on an interstate highway, causing injuries that led to the death of one, while leaving the other in serious condition. Seattle has...

Fire breaks out at multi-storey building in Kolkata

A fire broke out at a godown packed with plastic items on the second floor of a multi- storey building in Burrabazar area of the city on Sunday. Seven fire tenders rushed to the spot to put off the blaze, which erupted around 10 am, fire br...

Rugby-Hurricanes fight off red card to likely end Chiefs title hopes

The Wellington Hurricanes virtually ended the Waikato Chiefs Super Rugby Aotearoa title ambitions with a 25-18 victory on Sunday, despite playing almost the entire second half of their clash in Hamilton with 14 men. Hurricanes lock Scott Sc...

Give Feedback